title: The association between insulin levels and cortical bone: findings from a cross-sectional analysis of pQCT parameters in adolescents.
abstract: Recent studies suggest that patients with type 2 diabetes mellitus are at increased risk of fracture, possibly because hyperinsulinemia is a risk factor for low bone mineral density, which may in turn be a consequence of a lipotoxic effect of visceral and/or intramuscular fat on bone. In the current study, we investigated whether insulin plays a role in cortical bone development by performing a cross-sectional study based on the Avon Longitudinal Study of Parents and Children (ALSPAC), where we examined associations between fasting insulin levels and peripheral quantitative computed tomography (pQCT) parameters as assessed at the mid-tibia in 2784 boys and girls with a mean age 15.5 years. In particular, we wished to examine whether associations that we observed were independent of body composition, including intramuscular fat. We found that insulin was inversely related to cortical bone mineral density (BMD(C)) after adjustment for age and after further adjustment for height, muscle cross-sectional area (MCSA), subcutaneous fat (SAT), and muscle density (MD), which is inversely related to intramuscular fat (-0.018, 95% confidence interval [CI] -0.030, -0.006, p < 0.0001). Insulin was positively related to periosteal circumference (PC) after adjusting for age (0.015, 95% CI 0.003, 0.027, p = 0.015; beta = change per 50% increase in insulin), but this changed to an inverse association after additional adjustment for height and body composition (-0.013, 95% CI -0.022, -0.003, p = 0.008). Path analyses revealed inverse associations between insulin and PC via a direct pathway (-0.012, 95% CI -0.022, -0.003, p = 0.01) and via MD (-0.002, 95% CI -0.004, -0.001, p = 0.0004), and positive associations between insulin and PC via SAT (0.013, 95% CI 0.009, 0.016, p < 0.0001) and MCSA (0.015, 95% CI 0.010, 0.020, p < 0.0001). In conclusion, we found an inverse relationship between insulin and PC via intramuscular fat, suggesting a lipotoxic effect on bone. However, an inverse association between insulin and both PC and BMD(C) persisted after adjusting for all body composition variables, suggesting insulin also acts to inhibit bone development via additional pathways yet to be elucidated.
authors.affiliation: Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.
authors.forename: Adrian
authors.initials: A
authors.lastname: Sayers
authors.forename: Debbie A
authors.initials: DA
authors.lastname: Lawlor
authors.forename: Naveed
authors.initials: N
authors.lastname: Sattar
authors.forename: Jon H
authors.initials: JH
authors.lastname: Tobias
mesh_terms: D000293:Adolescent; D015519:Bone Density; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005215:Fasting; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D007328:Insulin
references.citation: Am J Epidemiol. 2007 Sep 1;166(5):495-505
references.pmid: 17575306
references.citation: Calcif Tissue Int. 2010 May;86(5):350-8
references.pmid: 20354685
references.citation: J Clin Endocrinol Metab. 2010 Nov;95(11):E368-72
references.pmid: 20668037
references.citation: Arch Dis Child. 1969 Jun;44(235):291-303
references.pmid: 5785179
references.citation: J Clin Endocrinol Metab. 2010 Mar;95(3):1247-55
references.pmid: 20080853
references.citation: J Bone Miner Res. 2010 Jun;25(6):1446-54
references.pmid: 20200928
references.citation: Cell. 2010 Jul 23;142(2):309-19
references.pmid: 20655471
references.citation: Menopause. 2010 Sep-Oct;17(5):955-61
references.pmid: 20613668
references.citation: Calcif Tissue Int. 1996 Dec;59(6):492-5
references.pmid: 8939777
references.citation: Paediatr Perinat Epidemiol. 2001 Jan;15(1):74-87
references.pmid: 11237119
references.citation: J Bone Miner Res. 2010 Dec;25(12):2760-9
references.pmid: 20641032
references.citation: J Clin Endocrinol Metab. 2011 May;96(5):E793-802
references.pmid: 21325463
references.citation: J Clin Endocrinol Metab. 2010 Feb;95(2):699-706
references.pmid: 20008022
references.citation: Osteoporos Int. 2007 Oct;18(10):1337-44
references.pmid: 17492393
references.citation: Endocrinology. 1992 Nov;131(5):2387-92
references.pmid: 1425437
references.citation: J Clin Endocrinol Metab. 2011 Jul;96(7):E1092-9
references.pmid: 21508147
references.citation: J Clin Endocrinol Metab. 2006 Sep;91(9):3404-10
references.pmid: 16804043
references.citation: J Clin Endocrinol Metab. 2001 Jan;86(1):32-8
references.pmid: 11231974
references.citation: Osteoporos Int. 2005 Dec;16(12):1713-20
references.pmid: 15940395
references.citation: J Clin Endocrinol Metab. 2010 Dec;95(12):5189-98
references.pmid: 20829185
references.citation: J Clin Endocrinol Metab. 2010 Nov;95(11):5045-55
references.pmid: 20719835
references.citation: Cell. 2007 Aug 10;130(3):456-69
references.pmid: 17693256
references.citation: BMJ. 2010 Nov 25;341:c6224
references.pmid: 21109577
references.citation: Diabetes Care. 2006 Nov;29(11):2427-32
references.pmid: 17065679
references.citation: J Pediatr. 2011 May;158(5):727-34
references.pmid: 21232765
references.citation: Osteoporos Int. 2012 Feb;23(2):635-41
references.pmid: 21424265
references.citation: Osteoporos Int. 2010 Mar;21(3):425-31
references.pmid: 19565174
references.citation: J Bone Miner Res. 2006 Dec;21(12):1871-8
references.pmid: 17002557
references.citation: Lancet. 1993 Jan 9;341(8837):72-5
references.pmid: 8093403
references.citation: J Bone Miner Res. 2010 Oct;25(10):2212-20
references.pmid: 20499348
references.citation: J Pediatr. 2011 May;158(5):698-700
references.pmid: 21353241
references.citation: J Bone Miner Res. 2011 Sep;26(9):2217-25
references.pmid: 21544865
references.citation: Curr Osteoporos Rep. 2011 Jun;9(2):67-75
references.pmid: 21374105
references.citation: Biochim Biophys Acta. 2010 Mar;1801(3):281-8
references.pmid: 19958841
references.citation: J Bone Miner Res. 2010 Feb;25(2):285-91
references.pmid: 19594301
references.citation: J Clin Endocrinol Metab. 2009 Sep;94(9):3387-93
references.pmid: 19531595